| Abstrakt: |
A new study on cancer vaccines, specifically RNA-based vaccines targeting patient-specific tumor neoepitopes, has been conducted by researchers at the National Cancer Institute (NCI). The study explores the potential of using combinations of "off-the-shelf" agents to stimulate the production of T cells directed against tumor-derived neoepitopes, leading to antitumor activity. The researchers acknowledge the challenges of developing patient-specific vaccines and the limitations of current algorithms in predicting neoepitopes. They propose that combination therapies involving agents to activate tumor-associated T-cell responses, potentiate those responses, reduce immunosuppression, and alter tumor cell phenotypes may offer an alternative approach to generating neoepitope vaccines. [Extracted from the article] |
